BCHE and Alzheimer disease: Tacrine, which was the first FDA-approved drug for AD treatment, is widely employed as an anticholinesterase pharmacophore to create multifunctional cholinesterase inhibitors possessing additional neuroprotective and disease-modifying properties [42,45,48,49,50,51,52,53].